Antipsychotic polypharmacy - Confusion reigns

Psychiatrist

Volumn 34, Issue 2, 2010, Pages 41-43

  Taylor, David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE;

DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG MECHANISM; MEDICAL PRACTICE; POLYPHARMACY; REVIEW; SCHIZOPHRENIA;

EID: 77951190799     PISSN: 17583209     EISSN: 17583217     Source Type: Journal    
DOI: 10.1192/pb.bp.109.027086     Document Type: Review

References (36)

1. Langan J, Shajahan P. Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist 2009; 34: 58-62.
2. Tungaraza TE, Gupta S, Jones J, Poole R, Slegg G. Polypharmacy and high-dose antipsychotic regimes in the community. Psychiatrist 2009; 34: 44-46
3. Paton C, Barnes TRE, Cavanagh MR, Taylor D, Lelliott P, the POMH-UK project team. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008; 192: 435-439 (Pubitemid 351809896)
4. Beasley Jr CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159-167 (Pubitemid 126424654)
5. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16: 158-169
6. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003; 64: 30-34 (Pubitemid 36182226)
7. Carpenter Jr WT, Zito JM, Vitrai J, Volavka J. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy? Biol Psychiatry 1998; 43: 79-83.
8. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW. Limbic selectivity of clozapine. Lancet 1997; 350: 490-491
9. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009; 35: 458-468
10. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009; 119: 419-425
11. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009; CD006324.
12. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35: 443-457
13. Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson M. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv 2007; 58: 983-990 (Pubitemid 47122878)
14. Taylor D, Holmes R, Hilton T, Paton C. Evaluating and improving the quality of risperidone prescribing. Psychiatr Bull 1997; 21: 680-683 (Pubitemid 27470748)
15. Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract 2000; 4: 41-46 (Pubitemid 30198335)
16. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325-329 (Pubitemid 28454819)
17. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161: 700-706 (Pubitemid 38445515)
18. Elie D, Poirier M, Chianetta J, Durand M, Gregoire C, Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol 2009; Epub ahead of print, doi: 10.1177/ 0269881108100777.
19. Taylor D, Young C, Esop R, Paton C, Walwyn R. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004; 185: 152-156 (Pubitemid 39061459)
20. Paton C, Esop R, Young C, Taylor D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004; 110: 299-305. (Pubitemid 39278989)
21. Taylor D, Young C, Mohamed R, Paton C, Walwyn R. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005; 19: 182-186 (Pubitemid 40577223)
22. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89: 91-100.
23. Connolly A, Taylor D. Ethnicity and quality of antipsychotic prescribing among in-patients in south London. Br J Psychiatry 2008; 193: 161-162
24. Ezewuzie N, Taylor D. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 2006; 20: 86-90.
25. Mace S, Taylor D. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2008; 23: 773-780
26. Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992; 149: 500-505
27. Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 2008; 22: 49-68.
28. Taylor D. Establishing a dose-response relationship for haloperidol decanoate. Psychiatr Bull 2005; 29: 104-107 (Pubitemid 40361353)
29. Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008; 28: 392-400.
30. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response. A double-blind PET study in schizophrenia. Neuropsychopharmacology 2006; 32: 1209-1215
31. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines (9th edn). Informa Healthcare, 2007.
32. Fleischhacker WW, Heikkinen T, Olie JP, Landsberg W, Dewaele P, McQuade RD, et al. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. Eur Psychiatry 2008; 2 (suppl 23): s114-5.
33. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007; 164: 1404-1410
34. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-389 (Pubitemid 34680462)
35. Taylor D. Antipsychotic prescribing - time to review practice. Psychiatr Bull 2002; 26: 401-402 (Pubitemid 35331231)
36. National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). NICE, 2009.